TriLink BioTechnologies & Avantor: A Strategic Partnership for European Biotech Growth

TriLink BioTechnologies, a Maravai LifeSciences company, has announced a strategic partnership with Avantor, Inc. to expand the availability of its innovative nucleic acid products across Europe, Middle East, and Africa (EMEA). This collaboration is expected to improve the ordering process and offer shorter lead times for European customers, increasing access to TriLink's cutting-edge nucleic acid technologies.

With over 25 years of experience in nucleic acid product development and manufacturing, TriLink is an established industry leader focused on advancing mRNA-based therapeutic innovations. Through the agreement, TriLink's products will now be more widely available in EMEA, including its CleanCap® cap analogs, catalog mRNAs, over 150 modified and unmodified nucleotides, and high-performance IVT enzymes like CleanScribe® RNA Polymerase. These products can be adapted for research use only (RUO) or manufactured at GMP-grade, catering to the diverse needs of the biotech industry.

Becky Buzzeo, Chief Commercial Officer at TriLink, expressed her enthusiasm about the partnership: "By collaborating with a trusted partner like Avantor and leveraging their unmatched distribution network, we can better serve the region’s growing demand for innovative solutions and support the advancement of life-changing therapeutic research."

The integration with VWR's MarketSource platform is a significant aspect of this partnership, as it will enhance TriLink's market penetration and accelerate order processing and fulfillment. This digital transformation is particularly important in the time-sensitive biotech research and development process, where rapid access to critical materials is crucial.

The strategic alliance with Avantor positions Maravai LifeSciences (MRVI) to better compete in the European biotech sector, addressing several critical market dynamics and creating long-term growth opportunities. By improving access and distribution, streamlining ordering processes, and enhancing the availability of proprietary technology, Maravai can capitalize on the expanding European biotech market.

In conclusion, the partnership between TriLink BioTechnologies and Avantor is a strategic move that will drive growth and innovation in the European biotech sector. By leveraging Avantor's distribution network and digital infrastructure, TriLink can better serve its customers and support the advancement of life-changing therapeutic research. As the European biotech sector continues to grow, this partnership positions Maravai LifeSciences for long-term success in the region.